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The term vasculitis covers heterogeneous disorders that share the presence of
inflammation of blood vessel walls. Immune cell infiltrates can vary significantly and
involve granulocytes or mononuclear cells. Vasculitis can be a symptom of other
underlying disorders or the underlying cause of organ specific or systemic disease.
Classification of childhood vasculitis is based on clinic, the size of predominantly affected
vessels, and the histopathology of inflammatory infiltrates. Timely and accurate diagnosis
and (where necessary) treatment initiation determine disease progression and outcomes.
In light of new developments and the identification of autoinflammatory conditions with
vasculitis, new classification tools may be discussed.
Keywords: vasculitis, inflammation, systemic disease, kawasaki disease, granulomatosis with polyangitis,
purpura, classification, paediatric
BACKGROUND
Vasculitis is an umbrella term for various and heterogeneous disorders sharing the presence
of inflammation of blood vessel walls. Immune cell infiltrates can vary significantly and
involve granulocytes (neutrophils, eosinophils) or mononuclear cells (monocytes/macrophages,
lymphocytes). Vasculitis can be a symptom of other underlying disorders (secondary vasculitis:
infections, medication intake, malignancies, autoimmune/inflammatory conditions, etc.) or the
cause of organ specific or systemic disease. In the latter case, the term “primary vasculitis” is used
(1).
It has been an ongoing challenge to classify childhood vasculitis, which is usually based
on clinical phenotypes (e.g., single organ vs. systemic vasculitis), the size of predominantly
affected vessels (small/medium/large), and the histopathology of inflammatory infiltrates
(e.g., granulomatous vs. non-granulomatous). The most commonly applied classifications are
the updated Chapel Hill consensus conference criteria for systemic vasculitis (2012) (2),
which have not been developed specifically for children, and the EULAR (European League
against Rheumatism)/PRES (Pediatric Rheumatology European Society)/PRINTO (Pediatric
Rheumatology International Trials Organization) classification criteria for childhood vasculitis (3–
5). Both sets of criteria are largely identical for primary systemic vasculitis (Figure 1) (with the
exception for giant cell arteritis), but show some differences for the classification of secondary forms
(Table 1) and vasculitis limited to single organ systems.
This manuscript provides an overview on current classification of childhood vasculitis,
focusing on primary systemic vasculitis. We deliver a brief summary on clinical signs, basic
pathomechanisms involved and treatment options. More comprehensive discussion of individual
forms of vasculitis, their molecular pathophysiology and treatment available is discussed in focused
manuscripts of this special topic.
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FIGURE 1 | Classification of primary childhood vasculitis based on revised Chapel Hill criteria (2012) and the EULAR/PRES classification (2–5).
TABLE 1 | Selection of underlying causes in secondary vasculitis.
Cause Example
Infections Viral: Hepatitis A/B/C, HIV, CMV
Bacterial: Neisseria, mycobacteria
Fungal: Candida, aspergillus
Malignancies Lymphoma, lymphoproliferative syndrome, etc.
Autoimmune SLE, MCTD, JDM, IBD, etc.
Medication, drugs Serum sickness, G-CSF, amphetamines, cocaine, heroin, etc.
Others Multiple
HIV, Human immunodeficiency virus; CMV, Cytomegaly virus; SLE, Systemic lupus
erythematosus; MCTD,Mixed connective-tissue disease; JDM, Juvenile dermatomyositis;
IBD, Inflammatory bowel disease; G-CSF, Granulocyte colony stimulating factor.
LARGE VESSEL VASCULITIS
Large vessel vasculitis (LVV) mainly affects large arteries and
includes giant cell arteritis (2). In childhood, primary LVV
is limited to Takayasu arteritis (TA). Temporal giant cell
arteritis, that predominantly involves the temporal artery, carotid
and/or vertebral arteries, does not occur in children (1, 3,
5). Takayasu arteritis (TA) is characterized by granulomatous
vasculitis of the aorta and/or its main branches, but also coronary
and/or pulmonary arteries (6, 7). While TA usually manifests
in the third or fourth decade, children (including infants)
and adolescents can develop disease. The exact incidence and
prevalence of TA in childhood is not known and variation
has been reported between geographical regions for adults
(UK: 0.8/million vs. Asia 2/million; likely 10–20% of who
are children) (8, 9). Girls and young women are more
frequently affected when compared to boys (3:1) (10). The
molecular pathophysiology of TA remains unclear, and genetic
factors, humoral, and cellular autoimmunological factors, as
well as infections have been discussed as contributors. Chronic
inflammation results in scarring and stenosis of large vessels
(6, 7).
Clinical presentation of TA is highly variable, ranging
from mild symptoms (e.g., arterial hypertension and/or weak
peripheral pulses) to cardiac and/or respiratory failure, and
further organ involvement (CNS, gastrointestinal system, etc.).
Disease stages prior to the development of key clinical
symptoms, such as “pulselessness,” are characterized by non-
specific symptoms associated with systemic inflammation and
include fever, night sweats, malaise, arthralgia, and myalgia.
As inflammation progresses, vascular stenosis develop and
may result in intermittent claudication, vascular bruits and/or
hypertension (11).
Diagnosis is usually based on EULAR/PRINTO/PRES
classification criteria (Table 2) and informed by imaging (usually
MRI angiography; Figure 2). Biopsies may be helpful in unclear
cases (10, 12, 13).
Treatment is guided by organ involvement and pre-
existing damage and is currently not standardized (14).
Pharmaceutical treatment involves corticosteroids as first-line
induction treatment (15), disease-modifying antirheumatic
drugs methotrexate (MTX), azathioprine (AZA), cyclosporine
A (CsA), and mycophenolate mofetil (MMF), TNF inhibitors
(infliximab/IFX, adalimumab/ADA, etanercept/ETA), IL-
6 inhibitors (Tocilizumab), and B cell depleting agents
(Rituximab/RTX) (14, 16–19). Furthermore, Cyclophosphamide
(CPM) can be discussed but should be reserved for otherwise
treatment refractory or acutely life-threatening cases. If
hemodynamically relevant vessel stenosis occur, interventional
or surgical interventions may be necessary, but should be avoided
if possible, since they are discussed to promote inflammation
(14).
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MEDIUM-SIZED VESSEL VASCULITIS
This group includes two forms of primary childhood vasculitis:
Kawasaki disease and polyarteritis nodosa.
Kawasaki disease (KD) is a systemic necrotizing vasculitis
of small and medium-sized vessels (20). A relatively common
and severe complication is the involvement of coronary arteries
that can result in aneurysms and cardiac infarction. KD is a
rare condition in adults. More than 90% of KD cases affect
children and infants (21). Globally, KD is the most common
TABLE 2 | EULAR/PRINTO/PRES criteria for TA.
Pathology in angiography
plus one of the following
Aorta or main branches, pulmonary arteries:
focal-segmental occluding or dilating
changes
exclude: arteriosclerosis and fibromuscular
dysplasia
(1) Absence of peripheral
pulses, claudication
Weak pulses over A. radialis and/or A. ulnaris;
muscle pain and/or weakness after minor exercise
(2) Asymmetrical BP >10 mmHg (systolic) difference between arms
(3) Murmur (70%) A. subclavia, A. carotis, abdominal aorta
(4) Hypertension >95. Percentile
(5) Systemic inflammation ESR > 20 mm/h, elevated CrP
BP, Blood pressure; CrP, C-reactive protein.
primary childhood vasculitis (Japan 239/100,000 children under
5 years), in predominantly Caucasian populations (9/100,000
children under 5 years), Henoch Schönlein purpura (HSP) is
more common (see below). The molecular pathophysiology of
KD is unclear (22–24). Genetic predisposition (BLK, CASP3,
CD40, FCGR2A, HLA class II, IPTKC), infectious triggers,
super antigens, humoral factors and immune complexes have
been suggested to contribute. In the acute phase of KD,
monocytes/macrophages and T cells produce pro-inflammatory
mediators that result in endothelial inflammation and the clinical
picture of KD (22, 23).
Most (75%) of patients develop KD before their 5th birthday.
By definition, fever without focus is present in all KD patients.
In children under 5 years-of-age, KD should be considered in the
case of unexplained fevers over 4–5 days (22, 23, 25). Infants are
less frequently but more severely (increased risk for aneurysm
development) affected and tend to exhibit “incomplete” clinical
pictures that can be challenging to diagnose (26). The term
“atypical KD” is reserved for children who fulfill diagnostic
criteria for KD, but experience a not typical disease course, which
may, amongst other symptoms include exudative pharyngitis
and/or conjunctivitis, aseptic meningitis, arthritis, and/or
anterior uveitis. Without timely establishment of treatment, 15–
25% of KD patients will develop coronary aneurysms, which
define prognosis and long-term outcomes (27). Diagnosis is
based on criteria summarized in Table 3 and Figure 3 (28, 29).
FIGURE 2 | Takayasu arteritis in a 12-year-old girl. (A) MRI angiography showing significant stenosis of the coeliac truncus (*) and lower aorta (→); artifacts are
caused by stent implants in renal arteries (L) (provided by Dr. Gabriele Hahn, Pädiatrische Radiologie, Universitätsklinikum Carl Gustav Carus, TU Dresden),
(B) transversal abdominal ultrasonography indicating significant stenosis of the coeliac truncus, (C) Stenosis of coeliac truncus resulting in pathologically increased
arterial blood flow velocity (provided by Dr. Heike Taut, Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, TU Dresden).
Consent of the patient was obtained to publish these images.
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Laboratory findings reflect systemic inflammation and include
elevated CRP (≥30 mg/l) and ESR (>40/h), elevated liver
enzymes (ALT ≥50 U/l), hypoproteinemia, elevated cholestasis
parameters, thrombocytosis, leukocytosis, and/or anemia (22).
Early and aggressive treatment of KD aims at symptom
alleviation and the prevention of vasculitis-associated damage
(such as aneurysms). Standard treatment includes salicylic
acid (initially during febrile period 30–50(−80) mg/kg/day,
followed by 3–5 mg/kg/day for 6–8 weeks), and intravenous
immunoglobulins (IVIG; usually 2 g/kg over 8–12 h). IVIG
should be applied within the first 7–10 days of fever to reduce
the risk for coronary aneurysms. Concomitant treatment with
prednisolone should be considered in KD patients with a high-
risk for the development of coronary aneurysms or individuals
who do not respond to a first course of IVIG. In otherwise
treatment refractory cases, cytokine-blocking strategies and other
have been discussed (22, 23, 27, 28, 30). Evidence for the
TABLE 3 | Clinical criteria for the diagnosis of “classical” KD (22).
Fever of unknown origin for ≥5 days plus 4 of the following if not
explained by another condition.
The diagnosis can also be made on day 4 in the presence of ≥4 principal
clinical criteria (particularly when redness and swelling of the hands and
feet are present)
• Bilateral Conjunctivitis (80–90%)
• Changes to oropharyngeal mucous membranes, including injected and/or
fissured lips, strawberry tongue and enanthema (80–90%)
• Palmar and/or plantar erythema and/or periungual desquamation (in
convalescent phase) (80%)
• Polymorphous exanthema, primarily truncal, not vesicular (>90%)
• (Mostly) cervical lymphadenopathy (at least one lymph node >1.5 cm) (50%)
usefulness of risk scores exists in Asian populations, but their
value in predominantly Caucasian populations remains unclear
(22, 31–33).
Panarteritis nodosa (PAN) is a necrotizing systemic vasculitis
of medium-sized vessels (3). Globally, after KD and HSP, PAN
is the third most common childhood primary vasculitis (34).
Recently, a rare disorder caused by loss-of-function mutations
in the ADA2 (or formerly CECR1) gene encoding for adenosine
deaminase 2 (ADA2) has been described and accounts for
a subset of particularly early-onset cases of PAN (Deficiency
of ADA2: DADA2) (35–37). The molecular pathophysiology
of remaining PAN cases is currently unclear. Interestingly,
increased incidence and prevalence was recorded in individuals
who experience Familial Mediterranean Fever (FMF), one of the
most common autoinflammatory disorders in childhood (38).
The result of transmural vessel inflammation is scarring and
(name giving) nodular changes to vessel walls and aneurysm
formation (24). For the diagnosis of PAN, classical angiography
and (at least in some patients) angio-MRI can be applied to
demonstrate vasal microaneurysms in affected organs (3, 39).
Though generally any organ system can be involved, most
patients develop vasculitis of the skin, musculoskeletal system,
kidneys and/or gastrointestinal system. Less frequently, the heart
and peripheral and/or central nervous system can be affected.
Initially, non-specific general symptoms, including fever and
malaise are common (5, 34). Diagnosis can be made bases on
EULAR/PRINTO/PRES criteria (Table 4) (3).
Because of the rarity of childhood PAN, widely accepted
and evidence-based treatment recommendations do not exist.
Treatment is usually informed by adult rheumatology and
includes corticosteroids, IVIG, DMARDS for maintenance
treatment, and/or CPM for severe cases (40, 41). Recently,
FIGURE 3 | Clinical criteria in KD. (A) Bilateral non-purulent conjunctivitis (80–90%), (B) changes to oropharyngeal mucous membranes, including injected and/or
fissured lips, strawberry tongue (80–90%), (C) Palmar, and/or (D) plantar erythema (E) polymorphous exanthema, primarily truncal, not vesicular (>90%), and (F,G)
cervical lymphadenopathy (>1.5 cm) (50%). (G) Ultrasound of enlarged cervical lymph nodes with increased perfusion (provided by Dr. Heike Taut, Klinik und Poliklinik
für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, TU Dresden). (H) Periungual desquamation (in covalescent phase) (80%), (I) Beau lines;
images from (22).
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anti-TNF agents have been demonstrated effective at least in a
subset of DADA2 patients (35).
SMALL VESSEL VASCULITIS
Small vessel vasculitis (SVV) predominantly affects parenchymal
arteries, arterioles, capillaries, and venules. Medium-sized
arteries and veins may also be affected. This group can
be subdivided into immune complex mediated and ANCA-
associated vasculitis.
While Henoch Schönlein purpura (HSP) is the most common
form of primary childhood vasculitis in Europe and North
America, it is significantly less common in adults (3–14 cases
per million) (42). Exact numbers on prevalence and incidence do
not exist secondary to very variable presentations and resulting
variability in medical needs and providers involved.
Henoch Schönlein purpura (HSP) is an immune complex
vasculitis with (mainly) IgA containing immune depositions
in small vessels. It can generally affect all age groups
(20/100,000/year), but is most common in 4–6 year-old children
(70/100,000/year). Boys are slightly more frequently affected as
compared to girls (1.2–2:1) (43).While the exact pathophysiology
of HSP is unknown, an association with previous infections
within the past 2–4 weeks has been recorded (44). As the result
of an unknown trigger mechanism, IgA containing immune
complexes deposit in small vessels and cause complement
activation, immune cell invasion, endothelial activation, and
lastly vasculitis (Figure 4).
Henoch Schönlein purpura (HSP) is a diagnosis of exclusion
and no specific diagnostic tests are available. Secondary immune
complex vasculitis and thrombocytopenic purpura require to be
excluded. To diagnose HSP, EULAR/PRINO/PRES classification
criteria are commonly used (Table 5) (3). Clinical presentation
is variable and, in addition to palpable purpura, includes
relatively common symptoms of abdominal pain, arthritis or
nephritis, as well as additional organ involvement and associated
complications (Table 6). Laboratory findings are unspecific and
include (usually) mildly elevated inflammatory parameters (ESR
and CrP), normal or slightly reduced serum C3 and/or C4, the
absence of high-titer autoantibodies (particularly ANCA and
TABLE 4 | EULAR/PRINTO/PRES criteria for PAN (3).
Criterion Frequency (%)
MAJOR CRITERIA (ONE HAS TO BE PRESENT)
Histological evidence Necrotizing vasculitis of small or medium-sized vessels –
Pathology on angiographic studies Aneurysm, vessel occlusion (exclude fibromuscular dysplasia or arteriosclerosis) –
MINOR CRITERIA (ONE HAS TO BE PRESENT)
Skin involvement Livedo reticularis, painful subcutaneous nodules, skin infarction, digital gangrene 70–90
Myalgia Myalgia and/or myogelosis 40–70
Arterial hypertension >95. Percentile 20–35
Peripheral neuropathy Mononeuritis multiplex, polyneuropathy 20
Kidneys Proteinuria, hematuria, kidney failure 20
FIGURE 4 | Pro-inflammatory mechanisms in immune complex vasculitis.
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TABLE 5 | EULAR/PRINTO/PRES criteria for HSP (3).
Criterion Frequency (%)
Palpable purpura
plus one of the
following
- Symmetric purpura, mainly over
extremities following gravity
- Exclude thrombocytopenia!
100
Abdominal pain - Colic-like, postprandial
- Nausea, gastrointestinal bleeding
- Intussusception, infarction, perforation
50
Histopathology - Immune complex vasculitis
- Proliferative glomerulonephritis (IgA
deposition)
–
Kidney involvement - Proteinuria >0.3 g/24 h or
- Albumin/creatinine ratio >30 mmol/mg
- Micro-hematuria
- Arterial hypertension
- Nephritic or nephrotic syndrome
20–40
Joint involvement - Arthritis, mostly ankles and/or knees 70
TABLE 6 | Non-cutaneous complications in HSP (45).
Complication Frequency (%)
Urogenital - Testicular bleeding
- Orchitis, urethral stenosis
5–10
CNS - Coma, ataxia, intracerebral bleeding
- DD: acute hypertensive crisis as a result of
kidney failure
2
Lungs - Reduced gas exchange capacity, pulmonary
bleeding
<1
ANA) and, in 50% of all cases, elevated serum IgA and/or
IgM (46). Fecal occult blood tests and urinary specimens
are recommended at diagnosis. Since glomerulonephritis can
manifest after the initial phase, regular urinary analysis at least
for the first 6 months after disease-onset are recommended.
Treatment depends on clinical presentation and organ
involvement. Non-steroidal anti-inflammatory drugs (NSAIDs)
or acetaminophen/paracetamol can be considered for analgesia
in cases with arthritis or arthralgia. For gastrointestinal
involvement treatment with corticosteroids (usually 1–2
mg/kg/day for 1 week, followed by taper over 2–3 weeks) can
be considered. However, intestinal perforations have been
seen under treatment (47, 48). Substitution of factor XIII can
be discussed for gastrointestinal bleedings. Of note, studies
indicate that early corticosteroids are not effective in preventing
HSP-associated nephritis (45, 49). Evidence for treatment is
weak, and expert recommendations have been provided e.g., by
the German Society for Pediatric Nephrology (GPN) (Table 7)
(50). Bed rest can be considered in severe cases.
The group of ANCA-associated vasculitis includes
granulomatosis with polyangitis (GPA, formerly Wegener’s
granulomatosis), eosinophilic granulomatosis with polyangitis
(EGPA, formerly Churg-Strauss syndrome), and microscopic
polyangitis (MPA). All of which are characterized by destructive
vasculitis of small andmedium-sized arterial vessels, the presence
of ANCA antibodies, and multi-organ involvement (1, 3, 4).
Granulomatosis with polyangitis (GPA) is rare in children.
Its incidence is estimated to be around 1/1,000,000. The mean
age at disease-onset is around 14 years. General symptoms,
including fevers, weight loss, and fatigue are present in over
90% of all patients. Diagnosis is usually made based on
EULAR/PRINTO/PRES classification criteria (Table 8) (3), and
additional symptoms can include arthritis, erythema, ulcerations,
and gastrointestinal involvement (Figure 5) (51).
Untreated, GPA has a mortality close to 100% within the
first year, and regardless of treatment, up to 60% of patients
experience subsequent disease flares. When compared to GPA in
adults, children, and young people more frequently experience
multi-organ involvement, kidney involvement, subglottic
stenosis and nose deformities (51, 52).
Eosinophilic granulomatosis with polyangitis (EGPA) is a
necrotizing vasculitis characterized by eosinophilic infiltrates in
small and medium-sized vessels (53, 54). Reliable demographic
information and/or classification criteria for the pediatric age-
group do not exist, and diagnosis is informed by ACR criteria
for adults with GPA (53). For classification as EGPA, four of six
criteria must be fulfilled: (i) Asthma, (ii) Eosinophilia (peripheral
blood) >10%, (iii) Mono- or polyneuropathy, (iv) pulmonary
infiltrates, (v) para-nasal sinus anomalies, and (vi) biopsy with
extra vascular eosinophilic infiltrates.
The exact pathophysiology of EGPA remains unclear.
Inappropriate Th2 activation and IL-4, IL-5, and Il-13 expression
play a central role and reflect parallels to allergic disease.
Progressive immune dysregulation triggers a prodromal state
that can last several years and include chronic sinusitis, allergies,
and severe corticosteroid-dependent asthma. Later, sinusitis,
pulmonary infiltrations and sometimes severe gastrointestinal,
cardiac, skin manifestations (Livedo, painful subcutaneous
lesions, infarctions, etc.), and peripheral neuropathy can be
present (54, 55).
Microscopic polyangitis (MPA), in contrast to GPA and
EGPA, is a non-granulomatous necrotizing vasculitis of
small vessels (56). Immune complex deposition is limited
or absent (pauci-immune vasculitis). Most patients develop
pulmonary (but not upper respiratory tract) involvement with
pulmonic hemorrhage and sometimes kidney involvement
(27%). Additional organ systems, including the gastrointestinal
system, CNS, skin, musculoskeletal system, and end eyes can be
affected. Diagnostic or classification criteria for childhood MPA
do not exist. Thus, Microscopic polyangitis (MPA) remains a
diagnosis of exclusions and is informed by adult rheumatology.
The presence of ANCA can be helpful (in adult cohorts: >50%
pANCA, 40% cANCA positive) (56, 57).
Treatment of childhood ANCA-associated vasculitis is guided
by disease severity. Generally, patients should receive more
or less aggressive induction treatment to control inflammation
(high-dose prednisolone or i.v. methylprednisolone pulses ±
CPM) that is followed by maintenance treatment with more
tolerable therapeutic agents (MTX, AZA, MMF) (58). Based on
studies in adult cohorts, RTX can be discussed as alternative
induction treatment in some cases and appears to be superior to
CPM in GPA flares after initial induction treatment with CPM
(59, 60). Trimetoprim/sufamethoxazole should be considered for
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pneumocystis prophylaxis. Furthermore, flare reduction has been
described in patients with GPA and S. aureus colonization (61,
62). In devastating and treatment-refractory cases, autologous
stem cell transplantation can be considered (63).
VASCULITIS AFFECTING VARIABLE
VESSEL SIZES
Several forms of vasculitis can affect vessels of variable types and
diameters.
Behcet’s disease (BD) is characterized by inflammatory lesions
in vessel walls of all sizes, which may lead to endothelial
damage, thrombosis, and aneurysms (64). Chronic recurrent oral
and/or genital ulcers occur can be accompanied by additional
cutaneous (erythema nodosum, cutaneous pustular vasculitis,
etc.), ocular (posterior uveitis, retinal vasculitis), articular (non-
erosive poly- or oligo-arthritis), gastrointestinal (abdominal pain,
nausea, diarrhea, etc.), and/or central nervous symptoms (aseptic
meningitis, vascular thrombosis) (1). Cases of BD can be seen
across the globe and in all ethnicities (64). However, prevalence is
highest in countries along the Silk Road, where it ranges between
77 and 100/100,000 individuals (0.1–15.9/100,000 in Western
Europe) (65, 66). While most patients develop symptoms in
young adulthood, 5–10% exhibit childhood-onset BD (67). The
pathophysiology of BD is incompletely understood, but genetic
associations are likely involved and may be influenced by
environmental factors (13, 68, 69). HLA-B51/B5 allele carriers
have considerably high risk for BD indicating a possible gene-
dose effect (70). Diagnosis can be challenging, especially since
children and young people frequently do not develop the
full clinical picture of BD and progress over time (64, 71).
More than 15 sets of classification or diagnostic criteria have
been published (72). Based on clinical differences between
age-groups, recently, pediatric classification criteria have been
suggested (1, 73). Treatment of BD can be complex and
should be informed by clinical symptoms and disease severity.
Topical treatment (steroids and/or sucralfate) and systemic
treatments (corticosteroids, colchicine, AZA, CsA, thalidomide,
apremilast, TNF inhibitors, etc.) are discussed elsewhere
(1, 64).
Cogan syndrome (CS) is characterized by predominantly
large vessel vasculitis, but can affect any vessel size (1). CS
is an extraordinarily rare multisystem inflammatory condition
that can involve eyes (keratitis, uveitis, episcleritis) and
inner ears (sensorineural deafness, vestibular dysfunction)
(2, 74). Unspecific systemic symptoms occur in 50% of all
patients, including arthralgia and manifestations of medium-
size and small vessel vasculitis. To date, only few pediatric
patients have been reported (75). Based on the rarity and
lack of pathophysiological understanding of the disorder,
data on effective treatments are lacking. Available reports
favor DMARDs (AZA, MTX) in combination with TNF
inhibitors (75).
TABLE 8 | EULAR/PRINTO/PRES criteria for GPA (3).
Criterion Frequency (%)
1. Histopathology - Granulomatous vasculitis of small
vessels
–
2. ENT - Chronic rhinitis/sinusitis
- Oral and/or nasal ulceration
- Nasal septum defect, saddle nose
- Mastoiditis, hearing loss, recurrent
epistaxis
80
3. Laryngo-tracheo-
bronchial system
- Subglottic, tracheal, bronchial stenosis 40
4. Lungs - Cough, dyspnea, obstruction
- Pulmonary bleeding
- Granuloma, cavernosis, infiltrates in
X ray or thorax CT
80
5. Kidneys - Proteinuria > 0.3 g/24 h or
- Albumin/creatinine ratio >30 mmol/mg
- Hematuria
- Necrotizing glomerulonephritis
75
6. ANCA antibodies - ANCA positivity (immune florescence,
ELISA)
90
TABLE 7 | Treatment recommendations for severe HSP nephritis (50).
1 (mild) 2 (moderate) 3 (nephrotic syndrome) 4 (kidney failure)
HSP STADIUM AND TREATMENT OPTIONS
Proteinuria
(g/g creatinine)
<2 >2
GFR
(ml/min/1.73 m2)
>90 <90
Serum albumine
(g/dl)
>2.5 <2.5
Kidney histology – No membrane
proliferation
Active nephritis, membrane proliferation
Therapeutic
options
– Ramiprile Ramiprile
+ Methylprednisolone
potentially additional
immune suppression
Ramiprile
+ Methylprednisolone
+ Cyclophosphamide
potentially additional
immune suppression
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FIGURE 5 | Findings in a 16-year-old boy with GPA. (A) Abdominal MRI showing pronounced parenchymatous necrosis of the spleen with distension of the spleen
capsule (provided by Dr. Gabriele Hahn, Pädiatrische Radiologie, Universitätsklinikum Carl Gustav Carus, TU Dresden); (B) Necrotizing skin vasculitis on legs and feet;
(C) Splenomegaly, spleen with increased echogenicity, subcapsular fluid accumulation, hypoechogenic necrotic areas with absence of perfusion (provided by Dr.
Heike Taut, Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, TU Dresden); (D) Severe enterocolitis (shown: transversal
colon) with deep ulcerations as a result of necrotizing vasculitis (provided by Dr. Martin Laass, Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum
Carl Gustav Carus, TU Dresden). Consent of the patient was obtained to publish these images.
SINGLE ORGAN VASCULITIS
Primary organ vasculitis covers a range of particularly rare
disorders characterized by vasculitis of a single organ in the
absence of signs indicative of systemic vasculitis (1). Various
organ systems can be involved, including the CNS (primary
large or small vessel CNS vasculitis) (76, 77), primary testicular
vasculitis (78), cutaneous leukocytoclastic vasculitis (1), etc.
VASCULITIS IN THE CONTEXT OF
AUTOINFLAMMATORY DISEASE
Autoinflammatory disorders are characterized by systemic or
organ-specific inflammation that is (at least initially) caused by
dysregulation of the innate immune system (79, 80). Vasculitis
can be a feature seen with several autoinflammatory conditions.
Indeed, in some autoinflammatory disorders, including
aforementioned BD (1, 81), previously discussed DADA2
(35–37), primary type I interferonopathies STING-associated
vasculopathy with onset in infancy (SAVI) (82) and Aicardi
Goutières syndrome (83), and haploinsufficiency of H20 (HA20)
(84), vasculitis can be the dominant feature. Autoinflammatory
conditions are still relatively “new” to the field of Rheumatology
and underlying pathomechanisms of systemic inflammation
and/or vasculitis remain unclear in many cases. Thus, (with the
exception of BD) vasculitis in the context of autoinflammatory
disease is not part of currently available classifications
for vasculitis, which will likely change in the years to
come.
CONCLUSIONS
Vasculitis are rare conditions in children and young people that
can be subdivided and classified based on clinical phenotypes
(e.g., organ-specific vs. systemic) underlying causes (primary
vs. secondary disease), histological patterns (granulomatous,
non-granulomatous, necrotizing, etc.), and primarily affected
vessel sizes (Chapel Hill and EULAR/PRES classifications:
small/medium/large). Timely and accurate diagnosis and (where
necessary) treatment initiation are essential, provided the
variable severity and outcomes of individual forms of vasculitis.
In light of new developments [including the identification of
genetic causes, sometimes resulting in expansion of disease-
associated phenotypes (e.g., DADA2)] and the identification
of autoinflammatory conditions with vasculitis as key feature
[including complex genetic BD, but also monogenic disease
(DADA2, SAVI, HA20)], new classification tools may be justified
in the near future.
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